Phase II trial of subcutaneous recombinant human interleukin 11 with subcutaneous recombinant human granulocyte-macrophage colony stimulating factor in patients with acute myeloid leukemia (AML) receiving high-dose cytarabine during induction: ECOG 3997

Leukemia Research

Volumn 30, Issue 7, 2006, Pages 823-827

  Cripe, Larry D ^a   Rader, Kevin ^b   Tallman, Martin S ^c   Gordon, Michael S ^d   Paietta, Elisabeth ^e   Bennett, John ^f   Neuberg, Donna ^b   Litzow, Mark R ^g   O'Brien, Timothy E ^h   Rowe, Jacob M ⁱ  

^a INDIANA UNIVERSITY MEDICAL CENTER   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d UNIVERSITY OF ARIZONA   (United States)

^e OUR LADY OF MERCY MEDICAL CENTER   (United States)

^f UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^g MAYO CLINIC   (United States)

^h CASE WESTERN RESERVE UNIVERSITY   (United States)

ⁱ RAMBAM MEDICAL CENTER   (Israel)

Author keywords

Acute myeloid leukemia; High dose cytarabine; Induction chemotherapy; Recombinant interleukin 11; Thrombocytopenia

Indexed keywords

CYTARABINE; DAUNORUBICIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 11;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AMINOTRANSFERASE BLOOD LEVEL; ANOREXIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DYSPNEA; EDEMA; FATIGUE; FEMALE; HEART ARRHYTHMIA; HUMAN; HYPERBILIRUBINEMIA; INCIDENCE; MALE; NAUSEA; NEUTROPHIL; PRIORITY JOURNAL; SIDE EFFECT; SOLID TUMOR; STATISTICAL ANALYSIS; STOMATITIS; SURVIVAL; THROMBOCYTE; THROMBOCYTOPENIA; TREATMENT OUTCOME; UREMIA;

ACUTE DISEASE; ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYTARABINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; INJECTIONS, SUBCUTANEOUS; INTERLEUKIN-11; LEUKEMIA, MYELOID; MALE; MIDDLE AGED; RECOMBINANT PROTEINS; REMISSION INDUCTION; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 33745437391     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2005.11.006     Document Type: Article

References (18)

1. Anderlini P., Luna M., Kantarjian H.M., O'Brien S., Keating M.J., and Estey E.H. Causes of initial induction failure in patients with acute myeloid leukemia and myelodysplastic syndromes. Leukemia 10 (1996) 600-610
2. Tornebohm E., Lockner D., and Paul C. A retrospective analysis of bleeding complications in 438 patients with acute leukemia during the years. Eur J Haematol 50 (1993) 160-167
3. Mayer R.J., Davis R.B., Schiffer C.A., Berg D.T., Powell B.L., Schulman P., et al. The Cancer and Leukemia Group B. Intensive postremission chemotherapy in adults with acute myeloid leukaemia. N Engl J Med 331 (1994) 896-903
4. Bishop J.F., Matthews J.P., Young G.A., Szer J., Gillettt A., Joshua D., et al. A randomized study of high-dose cytarabine in induction in acute myeloid leukemia. Blood 87 (1996) 1710-1717
5. Weick J.K., Kopecky K.J., Appelbaum F.R., Head D.R., Kingsbury L.L., Balcerzak S.P., et al. A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group Study. Blood 88 (1996) 2841-2851
6. Buchner T., Hiddemann W., Wörmann B., Löffler H., Gassmann W., Haferlach T., et al. Double induction strategy for acute myeloid leukemia: the effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine: a randomized trial by the German AML Cooperative Group. Blood 93 (1999) 4116-4124
7. Mitus A.J., Miller K.B., Schenkein D.P., Ryan H.F., Parsons S.K., Wheeler C., et al. Improved survival for patients with acute myelogenous leukemia. J Clin Oncol 13 (1995) 560-569
8. Matthews J.P., et al. Patterns of failure with increasing intensification of induction chemotherapy for acute myeloid leukaemia. Br J Haematol 113 (2001) 727-736
9. Rowe J.M., Andersen J.W., Mazza J.J., Bennett J.M., Paietta E., Hayes F.A., et al. A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (>55 to 70 years of age) with acute myelogenous leukemia: a study of the Eastern Cooperative Oncology Group (E1490). Blood 86 (1995) 457-462
10. Du X., and Williams D.A. Interleukin-11: review of molecular, cell biology, and clinical use. Blood 89 (1997) 3897-3908
11. Gordon M.S., McCaskill-Stevens W.J., Batitiato L.A., Loewy, Loesch D., Breeden E., et al. A phase I trial of recombinant human interleukin-11 (Neumega rhIL-11 Growth Factor) in women with breast cancer receiving chemotherapy. Blood 87 (1996) 3615-3624
12. Tepler I., Elias L., Smith J.W., Hussein M., Rosen G., Chang A.Y.C., et al. A randomized placebo-controlled trial of recombinant human interleukin-11 in patients with severe thrombocytopenia due to chemotherapy. Blood 87 (1996) 3607-3614
13. Isaacs C., Robert N.J., Bailey F.A., Schuster M.W., Overmoyer B., Graham M., et al. Randomized placebo-controlled study of recombinant human interleukin-11 to prevent chemotherapy-induced thrombocytopenia in patients with breast cancer receiving dose-intensive cyclophosphamide and doxorubicin. J Clin Oncol 15 (1997) 3368-3377
14. Slovak M.L., Kopecky K.J., Cassileth P.A., Harrington D.H., Theil K.S., Mohamed A., et al. Appelbaum FR for the Southwest Oncology Group and the Eastern Cooperative Oncology Group. Karyotypic analysis predicts outcome of pre-remission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood 96 (2000) 4075-4083
15. Cheson B.D., Bennet J.M., Kopecky K.J., Büchner T., Willman C.L., Estey E.H., et al. International working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. Revised recommendations of the International working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol 21 (2003) 4642-4649
16. Cassileth P.A., Harrington D.P., Appelbaum F.R., Lazaurs H.M., Rowe J.M., Paietta E., et al. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. N Engl J Med 339 (1998) 1649-1656
17. Archimbaud E., Ottmann O.G., Yin J.A., et al. A randomized, double-blind, placebo-controlled study with pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) as an adjunct to chemotherapy for adults with de novo acute myeloid leukemia. Blood 94 (1999) 3694-3701
18. Schiffer C.A., Miller K., Larson R.A., et al. A double-blind, placebo-controlled trial of pegylated recombinant human megakaryocyte growth and development factor as an adjunct to induction and consolidation therapy for patients with acute myeloid leukemia. Blood 95 (2000) 2530-2535